AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02602223 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Placing d-PTFE membrane over grafted site
Description: Selected teeth were extracted with minimal trauma to hard and soft tissues. The extraction sites were evaluated to verify presence of intact socket walls. Sockets were thoroughly debrided and a combination of demineralized freeze-dried bone and mineralized freeze-dried bone allograft from a single lot number (Maxxeus, Ohio, U.S.A) was placed in the sockets. Per randomization protocol d-PTFE membranes (Cytoplast, Osteogenics Medical, Texas, U.S.A) were tucked into the buccal and lingual flaps, which were minimally elevated (2-3mm) and d-PTFE sutures (Osteogenics Medical, Texas, U.S.A) were used to keep membrane in place. Primary closure was not attempted and membranes were intentionally left exposed
Study NCT01121380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL-1021
Description: BL-1021 is an orally available NCE which contains an elongated aliphatic side-chain.~Dosage:~Part 1 - Single Dose: 1 dose on Day 1, dosage will be 10, 20, 40 \& 80 mg according the cohort Part 2 - Multiple Dosing: up to 7 once-daily administrations. Dosage will be determined according the first part results.
Study NCT02173093 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: Given SC
Study NCT02173093 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory evaluations of immune responses
Description: Correlative studies
Study NCT00830895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Description: RAD001 10mg/day
Study NCT01121380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1021
Description: 1021
Study NCT03482934 — intervention group
Intervention type: DEVICE
Intervention: sphygmomanometer
Description: device used for measurement of brachial blood pressure
Study NCT03482934 — intervention group
Intervention type: DEVICE
Intervention: mobilogragh
Description: device used for measurement of central blood pressure
Study NCT03482934 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ECG
Description: Electrocardiogram
Study NCT03482934 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography
Description: Echocardiography
Study NCT01121380 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 1021
Description: 1021
Study NCT00766805 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EVL + Propranolol + Isosorbide 5 mononitrate
Description: Treatment was started with propranolol at a dose of 40 mg twice a day. The heart rate and blood pressure were checked after 12 to 24 hours. The dose of propranolol was increased at increments of 20 to 40 mg per day until the patient achieved a heart rate of 55 bpm, or a maximum dose of 320 mg/day was achieved.ISMN was added at a dose of 10 mg twice a day. The dose was escalated at increments of 10-20 mg/day till a maximum dose of 40 mg/day was reached.
Study NCT00766805 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: EVL alone
Study NCT00685594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cholecalciferol
Description: 20.000 IU cholecalciferol per week for 5 years versus placebo
Study NCT00685594 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule once a week, identical to cholecalciferol capsule
Study NCT01859247 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rTMS
Study NCT01859247 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: rTMS
Study NCT01119235 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PF-04531083
Description: Dosed as a tablet in 100mg strengths. Dosage in the first cohort will be 300mg twice daily for 3 days followed by 200mg twice daily for 11 days
Study NCT01119235 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PF-04531083
Description: Dosed as a tablet in 100mg strengths. Dosage in this optional second cohort will be optimised based on the data arising from Cohort 1
Study NCT03682120 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A/H7N9
Description: Monovalent inactivated, subunit influenza virus vaccine containing the HA and NA from influenza A/Hong Kong/125/2017 (H7N9) and the PB2, PB1, PA, NP, M and NS genes from A/Puerto Rico/8/1934 (H1N1).
Study NCT03682120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MF59
Description: Microfluoridized adjuvant 59 (MF59) is an oil-in-water emulsion.
Study NCT03682120 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phosphate Buffered Saline (PBS) diluent
Description: Diluent for Influenza Virus Vaccine.
Study NCT02184572 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Priorix
Description: 1 dose administered subcutaneously in the triceps region of left arm at Day 0
Study NCT02184572 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: M-M-R II
Description: 1 dose administered subcutaneously in the triceps region of left arm at Day 0
Study NCT02184572 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Varivax
Description: 1 dose administered subcutaneously in the triceps region of right arm at Day 0
Study NCT02184572 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Varivax
Description: 1 dose administered subcutaneously in the triceps region of right arm at Day 0
Study NCT02184572 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Havrix
Description: 1 dose administered intramuscularly in the anterolateral region of the right thigh at Day 0
Study NCT02184572 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Havrix
Description: 1 dose administered intramuscularly in the anterolateral region of the right thigh at Day 0
Study NCT02184572 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevnar 13
Description: 1 dose administered intramuscularly in the anterolateral region of the left thigh at Day 0 to subjects recruited in US
Study NCT02184572 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevnar 13
Description: 1 dose administered intramuscularly in the anterolateral region of the left thigh at Day 0 to subjects recruited in US
Study NCT02495038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10% reduction of combination of Esmeron® and Nimbex®
Description: Patients were randomly assigned to each group by opening of sealed allocation envelope. After collection of data, allocation number was matched with each group. The participants matched at Group S were administered with NMBAs reduced 10% of each ED95. Before patients arrived in the operating room, rocuronium and cisatracurium were prepared by a nurse who was not involved in this study. Each drug dosage was determined by allocation number. The syringe containing each study drug was conveyed to the performer of this study as the status of shielding the scale. The syringes of rocuronium and cisatracurium used each other syringe.
Study NCT02495038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20% reduction of combination of Esmeron® and Nimbex®
Description: The participants matched at Group L were administered with NMBAs reduced 20% of each ED95.
Study NCT03684369 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation
Description: Commercially available device will be used to apply weak electrical currents to arm and leg muscles in each of 18 treatment sessions.
Study NCT03684369 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcutaneous electrical nerve stimulation
Description: Commercially available device will be used to apply weak electrical currents to arm and leg muscles in each of 18 treatment sessions.
Study NCT02350764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nivolumab
Study NCT02350764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pilimumab
Study NCT03785223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate Hydrochloride Controlled-Release Capsules
Description: 25 mg methylphenidate hydrochloride- titrated as tolerated up to a maximum 4 capsules daily (25 mg- 100 mg total dose)~At Week 0 or Week 7, dosing will start at 1 capsule/day for one week, and be titrated to 2 capsules/day for Week 2. 50 mg of methylphenidate hydrochloride per day (i.e. 2 capsules/day) is the minimum dose that must be achieved. The dose may be titrated to 75 mg/day for Week 3 and to 100 mg/day for Week 4 if participants are tolerating their current dose, are experiencing no adverse events, and have not fully responded. By Week 4 or Week 11, no further dose changes will occur.
Study NCT03618056 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AIDSVAX® B/E
Description: Administered by intramuscular injection
Study NCT00591695 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stent bridge to surgery + elective surgery
Description: positioning in emergency of a metallic self-expanding stent followed, in case of successful colic decompression, by an elective surgical (laparoscopic or open) resection of the tumour
Study NCT00591695 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Emergency Surgery
Description: Emergency surgery performed in these ways: Resection followed by enterostomy (Hartmann procedure), 'On table' washing and primary anastomoses, Subtotal colectomy
Study NCT03897543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABX196
Description: ABX196 will be administered as an IM injection 120 minutes (+/- 15 minutes) after the completion of the nivolumab infusion on Day 1 of every other 28-Day treatment cycle (i.e., every 8 weeks).
Study NCT01970163 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DermACELL
Description: Acellular dermal matrix is applied at Baseline visit. The study product may be reapplied an additional time (between Weeks 2 and 12 for venous stasis ulcers and between Weeks 3 and 12 for diabetic foot ulcers).
Study NCT01970163 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: GraftJacket
Description: Acellular dermal matrix applied at Baseline visit. May be reapplied one additional time during study (between Week 2 and 12 for venous stasis ulcers and Week 3 and 12 for diabetic foot ulcers).
Study NCT01970163 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Conventional Care Dressings
Description: Depending on the state of the wound (dry or moist), different types of nonadherent dressings would be utilized as the primary dressing:~* If the wound is dry, a nonadherent dressing, such an oil emulsion dressing, may be appropriate, as these dressings tend to donate moisture to the wound.~* Hydrogels can also be used if the wound is in need of moisture.~* For a wound that is more moist, a more absorptive dressing may be more appropriate to help reduce potential for maceration.~A secondary dressing may be desired to add either loft or cushion.
Study NCT04935983 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High CHO
Description: Diet with high carbohydrate content
Study NCT04935983 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low CHO
Description: Diet with low carbohydrate content
Study NCT02758535 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: coaxial renal biopsy
Description: In this method, a larger introducing needle is used for the puncture. The introducing needle is advanced just to the outer cortex of the kidney, and the needle angle is adjusted so that the needle pathway became mostly in the renal cortex, then the biopsy needle is inserted throughout the introducing needle and at least 4 cores are obtained. In this technique, the skin surface is punctured only once during the procedure.
Study NCT02758535 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: noncoaxial renal biopsy
Description: In this method, introducing needle is not used. Biopsy needle punctures the skin surface and the needle is advanced to about 10-15 mm into the renal cortex, and tissue sampling is done. After each sampling, the needle is removed and then for the next biopsy, the whole procedure is repeated until four cores being taken.
Study NCT01515228 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Xience Prime
Description: everolimus-eluting stent implantation
Study NCT01515228 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cilotax stent
Description: paclitaxel with cilostazol dual drug eluting stent implantation
Study NCT03785223 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Capsule
Description: At Week 0 or Week 7, dosing will start at 1 capsule/day for one week, and be titrated to 2 capsules/day for Week 2. The dose may be titrated to 75 mg/day for Week 3 and to 100 mg/day for Week 4 if participants are tolerating their current dose, are experiencing no adverse events, and have not fully responded. By Week 4 or Week 11 no further dose changes will occur.
Study NCT02619916 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy (MBCT)
Description: The intervention consists of 8 weekly individual sessions of MBCT. Each session will be administered individually and will last 60 minutes
Study NCT02619916 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Description: The intervention consists of 8 weekly individual sessions of CBT. Each session will be administered individually and will last 60 minutes.
Study NCT01765959 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Auricular acupuncture (AA)
Description: Auricular acupuncture (AA) group will receive treatment twice a week for four weeks. Each session will take approximately 60 minutes in which there will be active treatment time for 40 minutes. During treatment the respondents will have 5 thin sterile, disposable steel needles superficially placed in each outer ear. Before needle insertion the outer ears will be cleaned with disinfection solution. During treatment the respondents will sit down in silence; with eyes shut and focus on a normal calm breathing. The acupuncturist will not be in the room during treatment. After 40 minutes the respondents remove the needles and put them in a box suited for disposed needles. If needed, assistance to remove needles will be given from the acupuncturist.
Study NCT03633084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBM-007 Injectable Solution
Description: (No additional description)
Study NCT01119547 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise in a group
Description: The patient do their individual exercise program in a group.
Study NCT01119547 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home exercise
Description: The patient exercise their individual program at home during 6 v.
Study NCT01557829 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Posterior lumbar interbody fusion with a PEEK cage
Description: PEEK cage suitable for oblique placement in the lumbar spine
Study NCT01557829 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Posterior lumbar interbody fusion with a Valeo OL cage
Description: Posterior lumbar interbody fusion with a single Valeo OL ceramic cage.
Study NCT01083667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrimethamine
Description: Open Label, dose escalating,
Study NCT02581254 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thin Wire Snare
Study NCT02581254 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thick Wire Snare
Study NCT00604968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caelyx (pegylated liposomal doxorubicin; SCH 200746)
Description: Caelyx will be administered intravenously at a dose of 40 mg/m\^2 on day one every 4 weeks until progression, or unacceptable toxicity, or other reason to discontinue the study treatment. The drug is diluted in 250 ml glucose 5% (500 ml for doses >=90 mg).
Study NCT01709188 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Musical Dual Task Training
Study NCT01709188 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Walking and Talking
Study NCT01439945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: magnesium oxide
Description: Given PO
Study NCT01439945 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given PO
Study NCT04082663 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dental Mouthpiece
Description: Participants will complete motor tasks with and without the dental mouthpiece during the in-person baseline visit. They will also be asked to wear the mouthpiece for one month, and complete sleep and quality of life questionnaires before and after wearing the mouthpiece.
Study NCT01893333 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nerve sparing radical hysterectomy
Description: Nerve sparing radical hysterectomy~1. sparing hypogastric nerve~2. sparing pelvic splanchnic nerve ad pelvic plexus in cardinal ligament~3. sparing distal part of hypogastric nerve and vesical branch of pelvic splanchnic nerve
Study NCT01893333 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nerve sparing radical hysterectomy
Description: Nerve sparing radical hysterectomy~1. sparing hypogastric nerve~2. sparing pelvic splanchnic nerve ad pelvic plexus in cardinal ligament~3. sparing distal part of hypogastric nerve and vesical branch of pelvic splanchnic nerve
Study NCT01172015 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood samples
Study NCT01172015 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: blood samples
Study NCT05438381 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Atraumatic Restorative Technique (ART)
Description: Glass ionomer capsule (GC, USA)
Study NCT05438381 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SMART Technique
Description: silver diamine fluoride (SDF) then glass ionomer cement capsule (GC, USA)
Study NCT04749381 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: acupoint with TCM
Description: The acupoint application was made of traditional Chinese medicine (TCM), and the therapeutic effect was produced through the stimulation of TCM drugs and acupoints.
Study NCT02123290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DSM265 xmg
Description: Dose of DSM265 to be determined based on the results of the first cohort
Study NCT04749381 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: acupoint with placebo
Description: The placebo acupoint application was made of black beans and honey, which shares the similar shape and smell of the experiment group, applied at the same acupoints.
Study NCT03828487 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Masimo O3 Neonatal Sensors
Description: Regional Oximetry sensor for Neonates
Study NCT03828487 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 510(k) cleared sensor
Description: Cleared Regional Oximetry sensor for Neonates
Study NCT01232478 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comprehensive Adherence Program (CAP)
Description: The Comprehensive Adherence Program (CAP) consists of training in the CF My Way program (a validated problem-solving adherence promotion intervention).
Study NCT02549716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV acetaminophen
Description: Patients in this group will receive IV acetaminophen and an oral placebo every 6 hours for a 14 day period. Blood and CSF samples will be collected from patients throughout the 14 day period.
Study NCT02549716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral acetaminophen
Description: Patients in this group will receive oral acetaminophen and an IV saline solution placebo every 6 hours for a 14 day period. Blood and CSF samples will be collected from patients throughout the 14 day period.
Study NCT02549716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral placebo
Description: Patients who receive IV acetaminophen will also receive an oral placebo with their IV treatments (every 6 hours for a 14 day period).
Study NCT02549716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV placebo
Description: Patients who receive oral acetaminophen will also receive a saline solution placebo at the same time that they receive the oral acetaminophen treatment (every 6 hours for 14 days).
Study NCT04418856 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Light Glasses (Experimental)
Description: The light glasses emit light from LEDs at a distance of 15 millimeters (15mm, 0.015.) from the eye. The device is classified as safe for the eyes in accordance with the international standard IEC 62471 and complies with the United States of America's FCC marking, and is designed to be worn on the participant's head, similar to a pair of glasses. For safety purposes, the light glasses do not contain UV or infra-red light.
Study NCT04418856 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Light Glasses (Comparison)
Description: The light glasses emit light from LEDs at a distance of 15 millimeters (15mm, 0.015.) from the eye. The device is classified as safe for the eyes in accordance with the international standard IEC 62471 and complies with the United States of America's FCC marking, and is designed to be worn on the participant's head, similar to a pair of glasses. For safety purposes, the light glasses do not contain UV or infra-red light.
Study NCT03158766 — intervention group
Intervention type: OTHER
Intervention: Microdiscectomy
Description: It will be an observational study without interventions. Subjects with diagnose of lumbar disc herniation undergoing open decompression surgery (microdiscectomy) will be included and analyzed. There will be no direct intervention to the patient proposed by the study.